Use of tumour-responsive T cells as cancer treatment

Mary L. Disis, Helga Bernhard, Elizabeth Jaffee

Research output: Contribution to journalArticle

Abstract

The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body-even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing tumours if they reoccur. We will highlight two direct methods of stimulating tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via adoptive T-cell treatment. Preclinical and clinical studies have shown that modulation of the tumour microenvironment to support the immune response is as important as stimulation of the most appropriate effector T cells. The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell.

Original languageEnglish (US)
Pages (from-to)673-683
Number of pages11
JournalThe Lancet
Volume373
Issue number9664
DOIs
StatePublished - 2009

Fingerprint

T-Lymphocytes
Neoplasms
Therapeutics
Neoplasm Antigens
Immunity
Immunologic Memory
Cancer Vaccines
Tumor Microenvironment
Vaccination
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Use of tumour-responsive T cells as cancer treatment. / Disis, Mary L.; Bernhard, Helga; Jaffee, Elizabeth.

In: The Lancet, Vol. 373, No. 9664, 2009, p. 673-683.

Research output: Contribution to journalArticle

Disis, Mary L. ; Bernhard, Helga ; Jaffee, Elizabeth. / Use of tumour-responsive T cells as cancer treatment. In: The Lancet. 2009 ; Vol. 373, No. 9664. pp. 673-683.
@article{cdd3df1bae3c4bce8539d80e00942c5a,
title = "Use of tumour-responsive T cells as cancer treatment",
abstract = "The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body-even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing tumours if they reoccur. We will highlight two direct methods of stimulating tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via adoptive T-cell treatment. Preclinical and clinical studies have shown that modulation of the tumour microenvironment to support the immune response is as important as stimulation of the most appropriate effector T cells. The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell.",
author = "Disis, {Mary L.} and Helga Bernhard and Elizabeth Jaffee",
year = "2009",
doi = "10.1016/S0140-6736(09)60404-9",
language = "English (US)",
volume = "373",
pages = "673--683",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9664",

}

TY - JOUR

T1 - Use of tumour-responsive T cells as cancer treatment

AU - Disis, Mary L.

AU - Bernhard, Helga

AU - Jaffee, Elizabeth

PY - 2009

Y1 - 2009

N2 - The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body-even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing tumours if they reoccur. We will highlight two direct methods of stimulating tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via adoptive T-cell treatment. Preclinical and clinical studies have shown that modulation of the tumour microenvironment to support the immune response is as important as stimulation of the most appropriate effector T cells. The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell.

AB - The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body-even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing tumours if they reoccur. We will highlight two direct methods of stimulating tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via adoptive T-cell treatment. Preclinical and clinical studies have shown that modulation of the tumour microenvironment to support the immune response is as important as stimulation of the most appropriate effector T cells. The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell.

UR - http://www.scopus.com/inward/record.url?scp=60249091474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249091474&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(09)60404-9

DO - 10.1016/S0140-6736(09)60404-9

M3 - Article

VL - 373

SP - 673

EP - 683

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9664

ER -